指南与共识泌尿生殖与妇科肿瘤放疗

局限期前列腺癌大分割放疗:ASTRO临床实践指南

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2026-10-27

该指南由美国放射肿瘤学会(ASTRO)组织多学科工作组制定,基于系统文献综述,针对局限期前列腺癌大分割外照射放疗提出循证推荐。指南推荐所有风险组接受中等大分割(MHF)优于常规分割;低危和中危患者可选择超大分割(UHF)作为标准治疗,高危患者可在临床试验背景下考虑UHF。

要点

  • 所有风险组局限期前列腺癌外照射均推荐MHF优于常规分割。
  • 低中危患者可选UHF作为标准治疗,高危患者宜在临床试验中考虑。
  • 分次方案选择通常独立于年龄、合并症和雄激素剥夺治疗。

核心结论

  • 大分割外照射已成为局限期前列腺癌根治性放疗的主要形式,成熟随机证据显示其结局与常规分割相当且降低治疗负担。

研究设计与样本

  • ASTRO召集多学科工作组,基于系统文献综述和预设共识方法制定,对证据质量和推荐强度进行分级,回答5个关键问题。

主要发现

  • MHF在所有风险组中均推荐优于常规分割,高质量随机数据证明肿瘤学结局、毒性和生活质量相当,且治疗疗程更短。
  • UHF推荐作为低危和中危患者选择根治性外照射时的标准治疗选项,高危患者可在临床试验背景下考虑。
  • 分次方案选择通常应独立于患者年龄、合并症和雄激素剥夺治疗的使用。
  • 对于基线有明显排尿功能障碍的患者,MHF可能优于UHF。
  • 证据支持使用当代图像引导的适形治疗技术以优化靶区覆盖并减少毒性。

关键数值与推荐

  • 指南提供了常用的MHF和UHF剂量分次方案指导。
  • 指南提供了靶区体积和盆腔淋巴结照射整合的指导。

临床怎么用

  • 局限期前列腺癌根治性外照射应优先选择MHF方案。
  • 低中危患者可与医生共同决策选择UHF;高危患者UHF宜在临床试验中应用。
  • 采用图像引导的适形放疗技术,并根据指南推荐确定剂量分次和靶区体积。

局限性

  • 高危患者UHF的应用需进一步研究,目前宜在临床试验背景下考虑。
  • 正在进行的研研究将进一步细化患者选择、UHF在高危疾病中的作用以及先进成像和自适应技术的整合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline provides evidence-based recommendations on the use of hypofractionated external beam radiation therapy (EBRT) in patients with localized prostate cancer, including indications for moderate hypofractionation (MHF) and ultrahypofractionation (UHF), appropriate dose-fractionation regimens, target volumes, and treatment planning and delivery techniques. METHODS: The American Society for Radiation Oncology convened a multidisciplinary task force to address 5 key questions related to hypofractionated EBRT in localized prostate cancer. Recommendations were based on a systematic literature review and developed using a predefined consensus-based methodology with grading of quality of evidence and strength of recommendation. RESULTS: MHF is recommended over conventional fractionation for patients receiving EBRT across all risk groups, supported by high-quality randomized data demonstrating equivalent oncologic outcomes, toxicity, and quality of life, with shorter treatment duration that may reduce overall treatment burden. UHF is recommended as a standard treatment option for patients with low- and intermediate-risk disease electing for definitive EBRT and may be considered in selected patients with high-risk disease, preferably in the context of clinical trials. Selection of fractionation should generally be independent of patient age, comorbidity, and use of androgen deprivation therapy, although MHF may be preferred over UHF for patients with significant baseline urinary dysfunction. Evidence supports the use of contemporary image-guided, conformal treatment techniques to optimize target coverage and minimize toxicity. Guidance is also provided regarding appropriate dose-fractionation regimens, including commonly used MHF and UHF schedules, as well as target volumes and integration of pelvic nodal irradiation. CONCLUSIONS: Hypofractionated EBRT has become the predominant form of definitive radiation therapy for localized prostate cancer, supported by mature randomized evidence demonstrating comparable outcomes to conventional fractionation and reduced treatment burden. Ongoing studies will further refine patient selection, the role of UHF in higher-risk disease, and integration of advanced imaging and adaptive technologies. These evidence-based recommendations inform best clinical practices in the use of hypofractionated EBRT for localized prostate cancer.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Morgan, Halthore, Jia, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2026. PMID: 42946126. doi:10.1016/j.prro.2026.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。